--The business combination of two AI-powered drug discovery and development companies, Recursion and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion ...

Recursion Halts Four Pipeline Programs, Sharpening Cancer, Rare Disease Focus AI drug developer advances fourth Sanofi-partnered program, earns $7M milestone payment ...

Recursion announces the close of a $121 million Series C financing to advance its machine learning-enabled approach to drug discovery and development.

Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.

Recursion's AI-Powered Drug Revolution Recursion is a clinical-stage TechBio company that is fundamentally built upon the principles of artificial intelligence and machine learning.